Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Mary Feng (ucsf)
Headshot of Mary Feng
Mary Feng

Description

Summary

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.

Official Title

Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI)

Details

Keywords

Eligibility

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at University of California Health

  • Mary Feng (ucsf)
    Dr. Mary Feng specializes in treating patients with cancers in the abdomen (gastrointestinal and hepatobiliary). Her approach is to make sure care is compassionate and coordinated. Her research uses advanced biology and technical advances to personalize and adapt radiation treatments for each patient to make treatment the most effective with the least amount of side effects.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04221893
Study Type
Interventional
Participants
Expecting 28 study participants
Last Updated